MARKETING:Picking Theratechnologies over bigger global firms assures TaiMed that its TMB355 HIV/AIDS drug would be given ‘top priority,’ the company said
Date: Apr 07, 2016
By: Ted Chen / Staff reporter
TaiMed Biologics Inc (中裕新藥) yesterday downplayed concerns about the company’s choice of distribution partner for its new HIV/AIDS drug TMB355, citing a robust business plan and advantages in tax management.
The company last month announced that it had inked an exclusive 12-year contract with Montreal-based Theratechnologies Inc to market its new drug in the US and Canada.
Analysts were downbeat on the partnership, casting doubts on the Canadian company’s ability to market the new drug compared with large companies.
“While Theratechnologies might not be a big name, marketing our product would be the company’s top priority,” TaiMed chief financial officer James Chen (陳怡成) said at an investors’ conference in Taipei.
Chen said larger companies might not be as motivated in marketing TMB355, as they tend to have many products in the mix, including their own new drug development initiatives. [FULL STORY]